Social Media and Cancer Screening Information

NCT06712901 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2030

Last updated 2026-03-20

Study results available
· View outcomes & findings →

Summary

NORC/AmeriSpeak will recruit participants who meet the study criteria and invite them to complete a 15-minute survey. Participants will be randomly assigned to one of five conditions, with approximately 400 people in each condition, and will respond to various questions after viewing the study messaging. Once 2,000 participants complete the survey, the data will be de-identified and provided to the study team for analysis.

Conditions

Interventions

BEHAVIORAL

Median Ranked Cancer Screening Messaging

Strong message content that increases screening and sharing intentions. Messages in this intervention were median ranked in the prior study.

BEHAVIORAL

Overall Preferred Cancer Screening Messaging

Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by all participants in the prior study.

BEHAVIORAL

Black American Preferred Cancer Screening Messaging

Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by Black participants but not White participants in the prior study.

BEHAVIORAL

White American Preferred Cancer Screening Messaging

Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by White participants but not Black participants.

BEHAVIORAL

Control

There will be no message content of cancer screening and sharing intentions in this arm.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • AmeriSpeak - NORC

    collaborator UNKNOWN
  • University of Utah

    lead OTHER

Principal Investigators

  • Andy King, PhD · Huntsman Cancer Institute/ University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-09
Primary Completion
2025-01-21
Completion
2025-01-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06712901 on ClinicalTrials.gov